论文部分内容阅读
目的:探讨β-微管蛋白Ⅰ编码基因TUBB基因的突变与多烯紫杉醇治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)耐药是否具有相关性。方法:用聚合酶链反应(polymerase chain reaction,PCR)和核苷酸测序技术检测90例晚期NSCLC患者TUBB基因是否存在突变。结果:36例患者在TUBB第4号外显子的第147号氨基酸编码序列处出现点突变,但这一突变与患者化疗疗效无明显相关。结论:β-微管蛋白Ⅰ的编码基因TUBB第4号外显子的第147号氨基酸编码序列的改变与多烯紫杉醇治疗NSCLC耐药无明显相关,但在患者中观察到了TUBB基因新的突变形式,该突变是否会对微管蛋白的结构和功能产生影响尚不确定,还需进一步深入研究。
OBJECTIVE: To investigate whether the mutation of TUBB gene of β-tubulin Ⅰ gene is associated with the drug resistance of docetaxel in the treatment of non-small cell lung cancer (NSCLC). Methods: The mutations of TUBB gene in 90 patients with advanced NSCLC were detected by polymerase chain reaction (PCR) and nucleotide sequencing. RESULTS: A total of 36 patients had a point mutation at the 147th amino acid coding sequence of exon 4 of TUBB, but this mutation was not significantly associated with the efficacy of chemotherapy in patients. CONCLUSION: The change of the amino acid sequence of amino acid 147 of TUBB exon 4, which is the coding gene of β-tubulin Ⅰ, is not significantly correlated with the drug resistance of docetaxel in the treatment of NSCLC. However, a new mutant form of TUBB gene was observed in patients Whether this mutation affects the structure and function of tubulin remains to be determined. Further study is needed.